Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A US federal appeals court has approved a request by Novartis and has temporarily prohibited Teva from selling its generic version of the antiviral medicine Famvir, which has various US patents valid until 2015.
Subscribe to our email newsletter
The order issued by the US Court of Appeals for the Federal Circuit, which has nationwide jurisdiction in various subject areas that include patents, requires Teva to submit a response to the court.
The injunction remains in effect until a decision by the court. Teva launched its generic version “at risk” since patent litigation is still ongoing, and risks potentially significant damages if Novartis prevails. A trial date has not been set.